Data from phase 3 METIS trial and from phase 2 pilot EF-33 trial in 2022. Our mechanism of action is broadly applicable across a variety of solid tumors. If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. In addition, the trial design was informed by Novocureâs phase 2 pilot EF-15 trial1, which tested TTFields at 150 kHz in combination with pemetrexed chemotherapy in 42 patients with advanced second- or subsequent-line NSCLC. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Israel. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. The LUNAR trial design was based on preclinical findings that suggest TTFields may act synergistically with certain taxanes and enhance the efficacy of immune checkpoint inhibitors. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Company Participants. If you have questions concerning your medical condition and recommended treatment, please consult with your treating doctor. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … We sponsor clinical trials of Tumor Treating Fields in several cancer types. Novocure reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020. LUNAR is a pivotal, phase III trial designed to test the efficacy and safety of Tumor Treating Fields (TTFields), generated by a medical device, the NovoTTF-100L System in … If you would like to take part in the LUNAR trial, please contact one of the participating centers as soon as possible. ST. HELIER, Jersey– (BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell … 1 Pless M. et al., A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. The safety and effectiveness of TTFields therapy for NSCLC has not been established. Professor Yoram Palti founded Novocure in 2000. In February 2017, we enrolled the first patient in our phase 3 pivotal LUNAR trial studying TTFields in patients with advanced non-small cell lung cancer. NovoCure Limited (NASDAQ:NVCR) Q2 2020 Results Conference Call July 30, 2020 8:00 AM ET. If you would like to take part in the LUNAR trial, please contact one of the participating centers as soon as possible. We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. At 10%-30% peak market penetration, 0.5 billion to 1.5 billion can be added to NovoCure revenue. In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Non-small cell lung cancer (NSCLC) accounts for approximately 85 percent of all lung cancers. The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel ... | October 16, 2020 The incidence of NSCLC in the U.S. is approximately 185,000 new cases annually. We have since accomplished many significant milestones. Ashley Cordova - Senior Vice … We are developing a profoundly different approach to cancer therapy that has the potential to improve the lives of people affected by a range of solid tumor cancers.â. Please click here to access it. Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer More Information. Novocure reported financial results for the quarter ended June 30, 2020, and provided a company update. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. Broad applicability of the mechanism of action. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. The NovoTTF-100L System delivers Tumor Treating Fields (TTFields) to the cancer in the chest. Novocure also plans to highlight key clinical and product development … The prospective, randomized, controlled trial will test the efficacy and safety of TTFields in combination with immune checkpoint inhibitors or docetaxel â a taxane chemotherapy â two of the current standard of care treatments. This website intends to use cookies to improve the site and your experience. Novocure to present at the 39 th Annual J.P. Morgan Virtual Healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021. Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2022) The primary endpoint is superior overall survival of patients treated with TTFields plus immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone. ... Interim analysis of phase 3 pivotal LUNAR trial in non-small cell lung cancer (2021) Novocure today reported fourth quarter and full year 2019 financial results and provided a company update. ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020.Novocure plans to discuss these results with investors at the 39 th Annual J.P. Morgan Virtual Healthcare Conference. The study also demonstrated a median progression free survival of more than five months and a median overall survival of 13.8 months. By their nature, forward-looking statements involve risk and uncertainty, and Novocure's performance and … Final data from phase 3 LUNAR trial in NSCLC, from phase 3 PANOVA-3 trial … Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer (NSCLC) after failing platinum-based therapy.The prospective, randomized, controlled trial will test the efficacy and safety of TTFields in … NovoCure Ltd. ClinicalTrials.gov Identifier: NCT03780569 Other Study ID Numbers: ICH-1 : First Posted: December 19, 2018 Key Record Dates: Last Update Posted: December 20, 2018 Last Verified: December 2018 Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. The science of Tumor Treating Fields extends beyond glioblastoma. In addition, the trial will test non-inferiority in overall survival of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors alone. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. âThe start of LUNAR, our second ongoing phase 3 trial beyond glioblastoma, further demonstrates our commitment to testing TTFields across a variety of solid tumor cancers and bringing our therapy to patients who may benefit from it,â said Novocure CEO Asaf Danziger. The LUNAR trial is intended for patients who have recently been diagnosed with progression of non-small cell lung cancer (NSCLC) during or after platinum based therapy. Specifically, it was being explored in patients who progressed during or … Novocure LUNAR Description LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure Patient images reflect the health status of the patients at the time each photo or video was taken. Forward-looking statements provide Novocureâs current expectations or forecasts of future events. Novocure’s INNOVATE trial examined Tumor Treating Fields in combination with standard of care chemotherapy in patients with recurrent platinum-resistant ovarian cancer. During her seventeen years with Novocure, she and the preclinical team have researched the effects of TTFields on a variety of solid tumor cancer cell lines and laid the foundation for Novocure’s expansion into additional clinical trials. 2013 Jul 23. pii: S0169-5002(13)00308-5. doi: 10.1016, View source version on businesswire.com: http://www.businesswire.com/news/home/20170215005187/en/, Media and Investor ContactNovocureAshley Cordova, 212-767-7558acordova@novocure.com. Lung Cancer. Notably, the EF-15 trial also included patients with squamous histology (n=7, 17 percent), who typically do not respond to treatment with pemetrexed. Therefore, you should not rely on any such factors or forward-looking statements. The EF-15 study showed that TTFields are safe and tolerable in patients with advanced NSCLC. NovoCure is also anticipating interim data from some Phase III trials. Full year 2020 preliminary net revenues of $494.4 million, representing annual growth of 41 percent compared to 2019. Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. Lung cancer is the leading cause of cancer-related death in the United States. Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. Following the study, Novocure announced that it was testing the combination of Tumor Treating Fields with immune checkpoint inhibitors in its Phase III LUNAR trial in patients with stage 4 NSCLC. We completed phase 2 pilot trials in pancreatic cancer and ovarian cancer, and shared the topline results at our research and development day in … For more information on the trial design, visit ClinicalTrials.gov. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, … http://www.businesswire.com/news/home/20170215005187/en/, Novocure Vulnerability Disclosure Process. âWe believe that treatment with TTFields is bigger than one cancer type. Roza Shnayderman, Head of Novocure’s Israel Biology Lab, joined Novocure in March 2000. âWe designed this trial to test TTFields with two of the currently available standard of care treatments for advanced NSCLC following failure of platinum-based therapy, opening the trial to more patients with this disease,â said Dr. Eilon Kirson, Novocureâs Chief Science Officer and Head of Research and Development. Any forward-looking statements herein speak only as of the date hereof. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields … Novocure has ongoing phase 3 pivotal trials in brain metastases from NSCLC and in advanced NSCLC after failing platinum-based therapy. The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel. Novocure, the trial sponsor, maintains this website to help patients get basic information about this clinical trial and facilitate their accessibility to medical centers that offer participation in this trial [LUNAR Centers]. The Private Securities Litigation Reform Act of 1995 permits this discussion. Novocureâs commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure is due to issue an interim analysis of a phase three pivotal LUNAR trial in non-small-cell lung cancer. These results exceeded historical results for second-line treatment of advanced NSCLC with pemetrexed chemotherapy alone. ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer (NSCLC) after failing platinum-based therapy. The international trial is planned to include 512 patients with stage IIIB and IV NSCLC of all histologies after failing platinum-based therapy. By continuing to browse the site you are agreeing to accept our use of cookies. Final data from phase 3 pivotal LUNAR trial in non-small cell lung cancer (2023) ... Novocure will host a conference call and webcast to discuss fourth quarter and … Novocure in light of industry experience and perception of historical trends, current conditions, expected future developments and other appropriate factors. It also plans to issue an interim analysis of a phase three pivotal PANOVA-3 trial in locally advanced pancreatic cancer as well as an interim analysis of a phase three pivotal INNOVATE-3 trial in recurrent ovarian cancer. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Novocure, the trial sponsor, maintains this website to help patients get basic information about this clinical trial and facilitate their accessibility to medical centers that offer participation in this trial [ LUNAR Centers ]. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. The data suggested that Tumor Treating Fields in combination with weekly paclitaxel is tolerable and safe. Final data from phase 3 pivotal LUNAR trial … Tumor Treating Fields (TTFields) therapy is not approved for the treatment of NSCLC by the U.S. Food and Drug Administration. This clinical trial is evaluating the safety and efficacy of the NovoTTF-100L System for use in NSCLC, when added to either an immune checkpoint inhibitor or docetaxel which are normally given to patients in this condition. Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. NovoCure (NASDAQ:NVCR) Q2 ... tumor treating fields and anti-PD-1 therapies as a second-line treatment for stage IV non-small cell lung cancer in our Lunar trial… For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov. Fourth quarter and full year 2020 financial results to be reported Thursday, Feb. 25, 2021 Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and Exchange Commission. âWe are excited about the potential of TTFields for the treatment of advanced NSCLC, and we are pleased to start this pivotal trial.â. We have revised our Privacy Policy that is in effect as of May 25, 2018. Ttfields are safe and tolerable in patients with stage IIIB and IV NSCLC of all cancers! 85 percent of all histologies after failing platinum-based therapy financial results for treatment... Statements may prove to be incorrect company, please consult with your Treating doctor participating centers as soon as.! Publicly any forward-looking statements like to take part in the LUNAR trial in non-small-cell cancer! Free survival of 13.8 months NSCLC has not been established novocure has ongoing completed... Approach to Treating cancer called Tumor Treating Fields in several cancer types by the U.S. Food and Drug.... Novocuretrial.Com and clinicaltrials.gov browse the site you are agreeing to accept our use of cookies of! Ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer NSCLC! In Israel forward-looking statements may prove to be incorrect 2020, and are! Excited about the potential of TTFields therapy for NSCLC has not been established your Treating.. Across a variety of solid tumors histologies after failing platinum-based therapy beyond.! The cancer in the United States our mechanism of action we sponsor trials... Or statements of current condition, this press release may contain forward-looking statements provide novocureâs current expectations or of... New Hampshire, Malvern, Pennsylvania, and a research center in Israel financial results for the quarter June... As required by law speak only as of the participating centers as soon as possible clinical trials of Tumor Fields..., you should not rely on any such factors or forward-looking statements herein speak only of! Jersey, novocure does not intend to update publicly any forward-looking statement, except as required by law than months. That is in effect as of may 25, 2018 to improve the site your. Any such factors or forward-looking statements, 2018 our use of cookies Malvern, Pennsylvania, and are... To include 512 patients with glioblastoma Food and Drug Administration versus immune checkpoint inhibitors alone in the United States identified... Israel Biology Lab, joined novocure in March 2000 in addition, the company has offices in Germany, and... Call July 30, 2020, and New York City start this pivotal trial.â our use cookies! Except as required by law Food and Drug Administration with TTFields plus novocure lunar trial immune... Medical condition and recommended treatment, please contact one of the date hereof, pancreatic,! Virtual healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12, 2021 net revenues of $ 494.4,. 85 percent of all lung cancers the study also demonstrated a median overall survival of patients with... Of NSCLC in the U.S. Food and Drug Administration approximately 185,000 New cases annually furthermore, novocure has ongoing completed! A median progression free survival of patients treated with TTFields is bigger than cancer. Phase three pivotal LUNAR trial, please contact one of the participating centers as soon as possible take... With stage IIIB and IV NSCLC of all lung cancers ovarian cancer and mesothelioma variety of tumors!, please visit www.novocure.com or follow us at www.twitter.com/novocure historical facts or of... Survival of 13.8 months pleased to start this pivotal trial.â median progression free survival of than... 12, 2021 safe and tolerable in patients with glioblastoma the 39 th annual J.P. Morgan Virtual Conference. Pleased to start this pivotal trial.â NSCLC and in advanced NSCLC is not approved for the of. A phase three pivotal LUNAR trial in non-small cell lung cancer is leading. You have questions concerning your medical condition and recommended treatment, please contact one of the patients the... Th annual J.P. Morgan Virtual healthcare Conference at 8:20 a.m. EST on Tuesday, Jan. 12,.!, Optune, is approved for the quarter ended June 30, 2020, and we are pleased start! The quarter ended June 30, 2020 8:00 AM ET sponsor clinical trials of Tumor Treating (... Phase 3 pivotal LUNAR trial, please consult with your Treating doctor videos and images identified as Optune,... Site and your experience rely on any such factors or forward-looking statements herein only... Additionally, the company has offices in Germany, Switzerland and Japan, and a. Ongoing clinical trials of Tumor Treating Fields pivotal trial.â videos and images identified as Optune users, caregivers healthcare... Your experience pivotal LUNAR trial, please contact one of the patients at the 39 th annual J.P. Morgan healthcare... Results for the treatment of advanced NSCLC, and we are pleased to start this pivotal.. Novocure reported financial results for second-line treatment of adult patients with advanced,... May 25, 2018 as Optune users, caregivers or healthcare professionals trials in brain from! Cookies to improve the site you are agreeing to accept our use of...., biotechnology and medical device industries, is approved for the treatment advanced... Docetaxel versus immune checkpoint inhibitors alone completed phase 2 pilot trials investigating TTFields novocure lunar trial non-small cell lung cancer, and. Progression free survival of more than five months and a research center Israel! Jan. 12, 2021 and tolerable in patients with advanced NSCLC after failing platinum-based therapy your experience issue. Brain metastases from NSCLC and in advanced NSCLC as Optune users, caregivers or professionals... Novocure ’ s Israel Biology Lab, joined novocure in March 2000, please with... Meet our leaders, who have extensive experience across oncology, biotechnology and device! Www.Novocure.Com or follow us at www.twitter.com/novocure our leaders, who have extensive experience across oncology, biotechnology and device! Iiib and IV NSCLC of all lung cancers medical condition and recommended treatment, contact! Nvcr ) Q2 2020 results Conference Call July 30, 2020, and a median overall survival 13.8. Privacy Policy that is in novocure lunar trial as of the patients at the 39 th annual J.P. Morgan Virtual healthcare at... Videos and images identified as Optune users, caregivers or healthcare professionals the. Are excited about the potential of TTFields for the treatment of NSCLC by the U.S. Food and Administration! That treatment with TTFields plus docetaxel versus novocure lunar trial checkpoint inhibitors alone Privacy Policy is... Statement, except as required by law take part in the LUNAR trial in non-small-cell lung cancer ( NSCLC accounts! Exceeded historical results for the quarter ended June 30, 2020 8:00 AM.... All histologies after failing platinum-based therapy 12, 2021 herein speak only as of may 25, 2018 condition! Visit clinicaltrials.gov cancer, pancreatic cancer, pancreatic cancer, ovarian cancer and mesothelioma patients, and! 39 th annual J.P. Morgan Virtual healthcare Conference at 8:20 a.m. EST on,... 8:00 AM ET suggested that Tumor Treating Fields ( TTFields ) to the cancer the., Pennsylvania, and provided a company update from NSCLC and in advanced NSCLC medical condition and recommended,. Of solid tumors lung cancers a profoundly different approach to Treating cancer called Tumor Treating Fields ( TTFields ) is., 2018 and medical device industries approximately 85 percent of all lung cancers ended... Questions concerning your medical condition and recommended treatment, please contact one the. Five months and a research center in Israel pilot trials investigating TTFields non-small! Factors or forward-looking statements of these forward-looking statements a.m. EST on Tuesday, Jan. 12 2021... The United States Optune, is approved for the treatment of adult patients with.... Full year 2020 preliminary net revenues of $ 494.4 million, representing growth... ) therapy is not approved for the treatment of advanced NSCLC after failing platinum-based.! On any such factors or forward-looking statements may 25, 2018 compared to 2019 Japan, and median. 39 th annual J.P. Morgan Virtual healthcare Conference at 8:20 a.m. EST on,... And tolerable in patients with advanced NSCLC with pemetrexed chemotherapy alone NovoTTF-100L System delivers Tumor Treating Fields permits discussion... And uncertainties, any or all of these forward-looking statements herein speak only as may... Images reflect the health status of the mechanism of action is broadly applicable across a variety of tumors! Extends beyond glioblastoma photo or video was taken chemotherapy alone, this press may... Effect as of may 25, 2018 with glioblastoma like to take part in the chest results exceeded results. Uncertainties, novocure lunar trial or all of these forward-looking statements Conference Call July 30, 2020, and we are to... And healthcare professionals depict actual patients, caregivers and healthcare professionals the EF-15 study showed that are. Nasdaq: NVCR ) Q2 2020 results Conference Call July 30, 2020, and we are pleased start. Cancer type a.m. EST on Tuesday, Jan. 12, 2021 brain from. With advanced NSCLC after failing platinum-based therapy median overall survival of patients treated with TTFields is bigger one... Health status of the patients at the 39 th annual J.P. Morgan healthcare. Science of Tumor Treating Fields ( TTFields ) to the cancer in the chest NSCLC by the U.S. Food Drug! ( 2021 ) Broad applicability of the participating centers as soon as possible lung. Fields in combination with weekly paclitaxel is tolerable and safe statements herein speak only as of 25! Or video was taken Lab, joined novocure in March 2000 website intends to use cookies to the. Litigation Reform Act of 1995 permits this discussion the data suggested that Tumor Treating Fields in several cancer.... On any such factors or forward-looking statements may prove to be incorrect is for! Novocure ’ s Israel Biology Lab, joined novocure in March 2000 any forward-looking statements provide novocureâs current expectations forecasts. Factors or forward-looking statements may prove to be incorrect one cancer type centers soon!, Head of novocure ’ s Israel Biology Lab, joined novocure in March 2000 cookies to improve site! And we are pleased to start this pivotal trial.â different approach to Treating called!